CNS Pharmaceuticals, Inc. Shareholders' Equity
CNS Pharmaceuticals, Inc. (CNSP) had Shareholders' Equity of $18.20 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $18.20M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $71.00K; Stockholders' Equity Attributable to Parent as first filed $70.70K.
- 2025-12-31: Stockholders' Equity Attributable to Parent $4.52M; Stockholders' Equity Attributable to Parent as first filed $4.52M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $9.91M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $18.20M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $71.00K 10-Q · filed 2026-08-12 | $70.70K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.52M 10-Q · filed 2026-08-12 | $4.52M 10-K · filed 2026-03-31 |
| 2025-09-30 | $9.91M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $13.13M 10-Q · filed 2026-08-12 | $13.12M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $10.97M 10-Q · filed 2026-08-12 | $10.97M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $6.18M 10-Q · filed 2026-08-12 | $6.18M 10-K · filed 2025-03-31 |
| 2024-09-30 | $3.35M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$4.29M 10-Q · filed 2025-11-14 | |
| 2024-03-31 | -$4.43M 10-Q · filed 2025-11-14 | -$4.43M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$4.43M 10-K · filed 2026-03-31 | |
| 2023-09-30 | -$1.74M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $2.45M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $3.49M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $8.13M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $7.57M 10-Q · filed 2023-11-14 | $8.39M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $10.70M 10-Q · filed 2023-11-14 | $11.52M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $13.98M 10-Q · filed 2023-11-14 | $14.80M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $6.16M 10-K · filed 2024-04-01 | $6.62M 10-K · filed 2022-03-03 |
| 2021-09-30 | $9.10M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $12.41M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $11.24M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $13.95M 10-K · filed 2023-03-31 | |
| 2020-09-30 | $2.47M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $3.72M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $5.88M 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $7.60M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $216.00 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $377.70K 10-Q · filed 2020-11-12 | |
| 2019-03-31 | -$716.78K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | -$549.30K 10-K · filed 2021-02-12 | |
| 2018-09-30 | -$347.03K 10-Q · filed 2019-12-20 | |
| 2018-06-30 | -$197.84K 10-Q · filed 2019-12-20 | |
| 2018-03-31 | $34.97K 10-Q · filed 2019-12-20 | |
| 2017-12-31 | -$58.53K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |